Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Therapy for cancer-related thromboembolism
Seminars in Oncology, Volume 41, No. 3, Year 2014
Notification
URL copied to clipboard!
Description
Cancer is an independent and major risk factor for venous thromboembolism (VTE), defined by symptomatic or asymptomatic DVT, including catheter-related thrombosis (CRT), and/or pulmonary embolism (PE). Over the past 20 years, VTE has become the second cause of death in cancer patients, where it accounts for increased morbidity, mortality, and healthcare costs. Incidental VTE is increasingly diagnosed on systematic computed tomography in cancer patients, raising new questions in daily oncology practice. Risk factors for VTE in cancer include patient-, cancer-, and treatment-related parameters, which vary for a single patient throughout the course of cancer disease and necessitate repeated individual risk assessments. The use of biomarkers and risk assessment models allow identification of cancer patients at high risk for VTE. Anticoagulant therapy for the prophylaxis and the treatment of established VTE is efficient and relatively safe when contraindications are respected, but the variety of risk factors and the number of comorbidities remain major challenges for adequate VTE treatment in cancer patients. Several national guidelines for primary prevention and treatment of VTE in cancer patients were issued in the past 10 years. To homogeneize existing Clinical Practice Guidelines (CPGs), an international consensus working group released specific guidelines for the treatment and prophylaxis of VTE in cancer patients in 2013, so as to make each CPG easier to use at the national level. In cancer patients treated for VTE, the use of low-molecular-weight heparins (LMWHs) is preferred over other anticoagulants in most cases, and LMWHs were shown to be superior to vitamin K antagonists (VKAs). For the prophylaxis of VTE, LMWHs have been validated in surgical patients. For medical cancer patients, ongoing or recent clinical trials will inform our practice. However, several questions remain unanswered due to the number of comorbities in a single patient and expert opinion regarding special situations is required. Better adherence worldwide to CPGs necessitates adequate educational and active implementation strategies, which could substantially decrease the burden of VTE and increase survival in cancer patients. © 2014 Elsevier Inc.
Authors & Co-Authors
Frére, Corinne
France, Marseille
Hopital la Timone
France, Marseille
Aix Marseille Université
Debourdeau, Philippe M.
France, Avignon
Institut Sainte Catherine
Hij, Adrian
France, Paris
Hôpital Saint-louis
Cajfinger, Francis
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Onan, Michel N.Guessan
Cote D'ivoire, Abidjan
Université de Cocody-abidjan
Panicot-Dubois, Laurence
France, Marseille
Aix Marseille Université
Dubois, Christophe
France, Marseille
Aix Marseille Université
Farge, Dominique C.
France, Paris
Hôpital Saint-louis
France, Paris
Inserm
Statistics
Citations: 29
Authors: 8
Affiliations: 7
Identifiers
Doi:
10.1053/j.seminoncol.2014.04.005
ISSN:
00937754
e-ISSN:
15328708
Research Areas
Cancer
Health System And Policy